Findings of Misconduct in Science, 67870-67871 [E6-19888]
Download as PDF
<![CDATA[
cprice-sewell on PROD1PC66 with NOTICES
67870
Federal Register / Vol. 71, No. 226 / Friday, November 24, 2006 / Notices
case studies to two children’s disorders
that appear to have environmental
etiologies but are less well understood:
disorders of lipid and carbohydrate
metabolism and attention deficit/
hyperactivity disorder (ADHD).
A discussion will follow each case
study presentation to consider the
opportunities, the barriers and the
design challenges that confront future
clinical, toxicological, epidemiological,
exposure monitoring, and basic research
in children’s environmental health.
Specific topics include:
• Past approaches to research
translation to see what worked and what
failed to work.
• The critical mass of researchers and
mix of disciplines needed to most
efficiently advance research in
children’s environmental health.
• Biomarkers of exposure,
susceptibility, or subclinical
dysfunction.
• The use of ‘‘omics’’ technologies
that might be incorporated into future
toxicological, epidemiological and/or
biomonitoring studies to enhance their
sensitivity and efficiency.
• Is there a point at which the use of
new scientific tools might slow the pace
of progress?
• New approaches to accelerating the
translation of science to treatment,
prevention, and the remediation of
environmental risks to children’s health.
• Potential study populations at
uniquely high risk of disease.
• Data resources—records, disease
registries, well-characterized cohort
populations, tissue banks, or stored
DNA—in the U.S. or abroad that might
facilitate future studies.
• New partnerships in research.
DATES: The workshop will be held on
January 22–23, 2007, at the NIEHS in
Research Triangle Park, North Carolina.
Individuals who plan to attend are
encouraged to register online at https://
www.apps.niehs.nih.gov/conferences/
od/cehr/ as soon as possible because
seating is limited. Please note that a
photo ID is required to access the NIEHS
campus. Persons needing special
assistance, such as sign language
interpretation or other reasonable
accommodation in order to attend,
should contact 919–541–2475 voice,
919–541–4644 TTY (text telephone),
through the Federal TTY Relay System
at 800–877–8339, or by e-mail to
niehsoeeo@niehs.nih.gov. Requests
should be made at least 7 days in
advance of the event.
ADDRESSES: The workshop will be held
in the Rodbell Auditorium, Rall
Building at the NIEHS, 111 T.W.
Alexander Drive, Research Triangle
Park, NC, 27709.
VerDate Aug<31>2005
13:24 Nov 22, 2006
Jkt 211001
Any
correspondence should be submitted to
Dr. Kristina Thayer (NIEHS, P.O. Box
12233, MD B2–01, Research Triangle
Park, NC, 27709; telephone: 919–541–
5021 or e-mail: thayer@niehs.nih.gov).
FOR FURTHER INFORMATION CONTACT:
Dated: November 9, 2006.
Samuel H. Wilson,
Deputy Director, National Institute of
Environmental Health Sciences and National
Toxicology Program.
[FR Doc. E6–19807 Filed 11–22–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI)
and the Assistant Secretary for Health
have taken final action in the following
case:
James C. Lin, Ph.D., University of
Illinois at Chicago: Based on the
findings from an inquiry by the
University of Illinois at Chicago (UIC)
and on additional analysis conducted by
ORI during its oversight review, the U.S.
Public Health Service (PHS) found that
James C. Lin, Ph.D., Professor,
Department of Electrical and Computer
Engineering, Physiology, and
Biophysics, UIC, engaged in research
misconduct concerning National
Institute of Neurological Disorders and
Stroke (NINDS), National Institutes of
Health (NIH), grant application 1 R01
NS47238–01, ‘‘Blood-Brain Barrier
Interactions of Cellular-Phone Radi.’’
Specifically, PHS found that Dr. Lin
committed research misconduct relative
to the legend and related text for Figure
2 (data from a colleague on other
experiments) for his NIH application 1
R01 NS47238–01, by falsely claiming
the figure represented preliminary
results of his independent experiments
that differed from the source of the
figure and the prior research in the field,
in which he purported to have
selectively exposed the rat’s head to
microwave irradiation, to have utilized
higher peak exposure, of shorter
duration and of different radio
frequencies, and which reported injury
of more acute nature to the blood
barrier.
Dr. Lin denies all allegations of
research misconduct and contends that
some of his original data is missing as
a result of the involuntary relocation of
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
his laboratory. Dr. Lin makes no
admission of guilt in connection with
the charges or PHS’ findings of research
misconduct herein. Both Dr. Lin and
PHS are desirous of concluding this
matter without further expense of time
and other resources.
Dr. Lin has entered into a Voluntary
Exclusion Agreement in which he has
voluntarily agreed, for a period of three
(3) years, beginning on October 24,
2006:
(1) That any institution which
submits an application for PHS support
for a research project on which Dr. Lin’s
participation is proposed or which uses
him in any capacity on PHS supported
research, or that submits a report of
PHS-funded research in which Dr. Lin
is involved, must concurrently submit a
plan for supervision of Dr. Lin’s duties
to the funding agency for approval. The
supervisory plan must be designed to
ensure the scientific integrity of his
research contribution. Dr. Lin agrees to
ensure that a copy of the supervisory
plan also is submitted to ORI by the
institution. He also agrees that he will
not participate in any PHS-supported
research until such a supervision plan is
submitted to ORI;
(2) that any institution employing Dr.
Lin submit in conjunction with each
application for PHS funds or reports,
manuscripts, or abstracts of PHS-funded
research in which Dr. Lin is involved a
certification that the data provided by
Dr. Lin are based on actual experiments
or are otherwise legitimately derived
and that the data, procedures, and
methodology are accurately reported in
the application or report. Dr. Lin must
ensure that the institution also sends a
copy of the certification to ORI; and
(3) to exclude himself from serving in
any advisory capacity to PHS, including
but not limited to service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E6–19889 Filed 11–22–06; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Misconduct in Science
AGENCY:
E:\FR\FM\24NON1.SGM
Office of the Secretary, HHS.
24NON1
Federal Register / Vol. 71, No. 226 / Friday, November 24, 2006 / Notices
cprice-sewell on PROD1PC66 with NOTICES
ACTION:
Notice.
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI)
and the Assistant Secretary for Health
have taken final action in the following
case:
Clifford R. Robinson, Ph.D., University
of Delaware: Based on the reports of
investigations conducted by 3Dimensional Pharmaceuticals, Inc.
(3DP) and the University of Delaware
(UD) and additional analysis conducted
by ORI during its oversight review, the
U.S. Public Health Service (PHS) found
that Clifford R. Robinson, Ph.D.,
Assistant Professor, Department of
Chemistry and Biochemistry, UD,
engaged in misconduct in science
involving research supported by
National Institute of General Medical
Sciences (NIGMS), National Institutes of
Health (NIH), grants 1 R43 GM58950–01
and 2 R44 GM58950–02, ‘‘Four-helix
bundle analog of a G-protein coupled
receptor (C. Robinson, Principal
Investigator [P.I.]). The following grant
applications also were involved in Dr.
Robinson’s misconduct in science:
1 R43 GM62708–01, ‘‘Improved
method for protein refolding’’ (C.R.
Robinson, P.I.), submitted March 30,
2000; approved but not funded,
withdrawn.
1 P20 RR017716–01, ‘‘Design of
hierarchical recognition motifs,’’ Project
V, ‘‘Determinants of stability and
assembly of integral membrane
proteins’’ (C.R. Robinson, Project
Investigator), submitted March 1, 2002,
funded September 16, 2002, to August
30, 2007.
1 R01 GM074789–01, ‘‘Folding and
stability of integral membrane proteins’’
(C.R. Robinson, P.I.), submitted October
1, 2004; scored not competitive, not
funded.
1 R01 GM075891–01, ‘‘Membrane
protein expression, solubilization, and
refolding’’ (C.R. Robinson, P.I.),
submitted January 24, 2005; approved
but not funded, pending.
1 R21 GM07953–01, ‘‘Mini-receptor
analogs of GPCRs’’ (C.R. Robinson, P.I.),
submitted January 25, 2005; not funded.
Specifically, PHS found that Dr.
Robinson engaged in the following acts
of misconduct in science. With regard to
the following paragraphs numbered 1–6,
nothing herein shall be deemed as an
admission of liability on the part of Dr.
Robinson.
1. While at 3DP, Dr. Robinson
systematically substituted crystallized
chicken ovalbumin in place of b2–AR–
NQ and repeatedly provided these
crystalline preparations to other
scientists to conduct molecular
analyses. Dr. Robinson made false
VerDate Aug<31>2005
13:24 Nov 22, 2006
Jkt 211001
claims about his progress on
characterizing b2–AR–NQ and falsely
claimed to have supplied purified b2–
AR–NQ to 3DP staff in project team
meetings (PTM) held on at least five
occasions between July 14, 1998, and
July 7, 1999.
2. Dr. Robinson made multiple false
claims about his research on b2–AR–NQ
in NIH grant applications R44
GM58950–02, submitted April 1, 1999,
supplemental material for the same
application submitted on July 7, 1999,
and NIH grant application R43
GM62708–01, submitted March 30,
2000.
3. Dr. Robinson made similar claims
as in item 1 above concerning the wild
type form of b2–AR, by substituting
canine ovalbumin. Dr. Robinson’s false
claims were made to 3DP staff at PTM
meetings on at least three occasions
between September 7, 1999, and March
30, 2000, and in NIH grant application
R43 GM62708–01, and after moving to
UD, in NIH grant application 1 P20
RR017716–01, submitted on March 1,
2002.
4. Dr. Robinson was unable to
adequately produce recombinant b2–AR
in E. coli and made false claims at PTM
meetings in September and October
1999 that he had successfully expressed
active protein and had purified it for
crystallization trials. Dr. Robinson also
made false claims in NIH grant
applications R43 GM62708–01 and 1
R01 GM07589–01, submitted January
24, 2005, that he had purified large
amounts of b2–AR–NQ from E. coli and
that he had reconstituted the protein
into its native biologically active form.
5. Dr. Robinson made false claims
about his ability to produce, purify, and
characterize a recombinant fragment of
b2–AR–NQ containing four
transmembrane domains (b2–AR–4HB)
at PTM meetings in October 1998 and in
NIH grant applications R44 GM58950–
02 and 1 P20 RR017716–01.
6. Dr. Robinson falsified fluorescence
spectra and circular dichroism
measurements in Figure 7 (both left and
right panels) of NIH grant application
R44 GM58950–02 by substituting results
obtained with different proteins.
7. After moving to UD, Dr. Robinson
made false claims in NIH grant
application 1 P20 RR017716–01,
including presenting falsified data in
both panels of Figures V.5 (fluorescence
spectra and circular dichroism
measurements) and V.9 (falsified
experimental conditions).
8. While at UD, Dr. Robinson falsified
circular dichroism and fluorescence
data in NIH grant application 1 R01
GM074789–01 (Figures 5A, 5B, and 6)
and circular dichroism data in NIH
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
67871
grant applications 1 R01 GM075891–01
(Figure 6) and 1 R21 GM075953–01
(Figure 5).
9. In presentations at the Biophysical
Society annual meeting and a Cornell
University Consortium meeting, both in
1999, Dr. Robinson falsely represented
data obtained with cytochrome b562 as
being obtained with b2–AR.
Dr. Robinson has entered into a
Voluntary Exclusion Agreement in
which he has voluntarily agreed, for a
period of five (5) years, beginning on
October 23, 2006:
(1) To exclude himself from any
contracting or subcontracting with any
agency of the United States Government
and from eligibility for or involvement
in nonprocurement programs of the
United States Government as defined in
the debarment regulations at 45 CFR
Part 76; and
(2) to exclude himself from serving in
any advisory capacity to PHS, including
but not limited to service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E6–19888 Filed 11–22–06; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Toxic Substances and
Disease Registry
[ATSDR–226]
Availability of Final Toxicological
Profiles
Agency for Toxic Substances
and Disease Registry (ATSDR),
Department of Health and Human
Services (HHS).
ACTION: Notice of availability.
AGENCY:
SUMMARY: This notice announces the
availability of one new and five updated
final toxicological profiles of priority
hazardous substances comprising the
eighteenth set prepared by ATSDR.
FOR FURTHER INFORMATION CONTACT: Ms.
Olga Dawkins, Division of Toxicology
and Environmental Medicine, Agency
for Toxic Substances and Disease
Registry, Mailstop F–32, 1600 Clifton
Road, NE., Atlanta, Georgia 30333,
telephone (770) 488–3315. Electronic
access to these documents is also
E:\FR\FM\24NON1.SGM
24NON1
]]>Agencies
[Federal Register Volume 71, Number 226 (Friday, November 24, 2006)]
[Notices]
[Pages 67870-67871]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-19888]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Misconduct in Science
AGENCY: Office of the Secretary, HHS.
[[Page 67871]]
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) and the Assistant Secretary for Health have taken final action in
the following case:
Clifford R. Robinson, Ph.D., University of Delaware: Based on the
reports of investigations conducted by 3-Dimensional Pharmaceuticals,
Inc. (3DP) and the University of Delaware (UD) and additional analysis
conducted by ORI during its oversight review, the U.S. Public Health
Service (PHS) found that Clifford R. Robinson, Ph.D., Assistant
Professor, Department of Chemistry and Biochemistry, UD, engaged in
misconduct in science involving research supported by National
Institute of General Medical Sciences (NIGMS), National Institutes of
Health (NIH), grants 1 R43 GM58950-01 and 2 R44 GM58950-02, ``Four-
helix bundle analog of a G-protein coupled receptor (C. Robinson,
Principal Investigator [P.I.]). The following grant applications also
were involved in Dr. Robinson's misconduct in science:
1 R43 GM62708-01, ``Improved method for protein refolding'' (C.R.
Robinson, P.I.), submitted March 30, 2000; approved but not funded,
withdrawn.
1 P20 RR017716-01, ``Design of hierarchical recognition motifs,''
Project V, ``Determinants of stability and assembly of integral
membrane proteins'' (C.R. Robinson, Project Investigator), submitted
March 1, 2002, funded September 16, 2002, to August 30, 2007.
1 R01 GM074789-01, ``Folding and stability of integral membrane
proteins'' (C.R. Robinson, P.I.), submitted October 1, 2004; scored not
competitive, not funded.
1 R01 GM075891-01, ``Membrane protein expression, solubilization,
and refolding'' (C.R. Robinson, P.I.), submitted January 24, 2005;
approved but not funded, pending.
1 R21 GM07953-01, ``Mini-receptor analogs of GPCRs'' (C.R.
Robinson, P.I.), submitted January 25, 2005; not funded.
Specifically, PHS found that Dr. Robinson engaged in the following
acts of misconduct in science. With regard to the following paragraphs
numbered 1-6, nothing herein shall be deemed as an admission of
liability on the part of Dr. Robinson.
1. While at 3DP, Dr. Robinson systematically substituted
crystallized chicken ovalbumin in place of [beta]2-AR-NQ and
repeatedly provided these crystalline preparations to other scientists
to conduct molecular analyses. Dr. Robinson made false claims about his
progress on characterizing [beta]2-AR-NQ and falsely claimed
to have supplied purified [beta]2-AR-NQ to 3DP staff in
project team meetings (PTM) held on at least five occasions between
July 14, 1998, and July 7, 1999.
2. Dr. Robinson made multiple false claims about his research on
[beta]2-AR-NQ in NIH grant applications R44 GM58950-02,
submitted April 1, 1999, supplemental material for the same application
submitted on July 7, 1999, and NIH grant application R43 GM62708-01,
submitted March 30, 2000.
3. Dr. Robinson made similar claims as in item 1 above concerning
the wild type form of [beta]2-AR, by substituting canine
ovalbumin. Dr. Robinson's false claims were made to 3DP staff at PTM
meetings on at least three occasions between September 7, 1999, and
March 30, 2000, and in NIH grant application R43 GM62708-01, and after
moving to UD, in NIH grant application 1 P20 RR017716-01, submitted on
March 1, 2002.
4. Dr. Robinson was unable to adequately produce recombinant
[beta]2-AR in E. coli and made false claims at PTM meetings
in September and October 1999 that he had successfully expressed active
protein and had purified it for crystallization trials. Dr. Robinson
also made false claims in NIH grant applications R43 GM62708-01 and 1
R01 GM07589-01, submitted January 24, 2005, that he had purified large
amounts of [beta]2-AR-NQ from E. coli and that he had
reconstituted the protein into its native biologically active form.
5. Dr. Robinson made false claims about his ability to produce,
purify, and characterize a recombinant fragment of [beta]2-
AR-NQ containing four transmembrane domains ([beta]2-AR-4HB)
at PTM meetings in October 1998 and in NIH grant applications R44
GM58950-02 and 1 P20 RR017716-01.
6. Dr. Robinson falsified fluorescence spectra and circular
dichroism measurements in Figure 7 (both left and right panels) of NIH
grant application R44 GM58950-02 by substituting results obtained with
different proteins.
7. After moving to UD, Dr. Robinson made false claims in NIH grant
application 1 P20 RR017716-01, including presenting falsified data in
both panels of Figures V.5 (fluorescence spectra and circular dichroism
measurements) and V.9 (falsified experimental conditions).
8. While at UD, Dr. Robinson falsified circular dichroism and
fluorescence data in NIH grant application 1 R01 GM074789-01 (Figures
5A, 5B, and 6) and circular dichroism data in NIH grant applications 1
R01 GM075891-01 (Figure 6) and 1 R21 GM075953-01 (Figure 5).
9. In presentations at the Biophysical Society annual meeting and a
Cornell University Consortium meeting, both in 1999, Dr. Robinson
falsely represented data obtained with cytochrome b562 as being
obtained with [beta]2-AR.
Dr. Robinson has entered into a Voluntary Exclusion Agreement in
which he has voluntarily agreed, for a period of five (5) years,
beginning on October 23, 2006:
(1) To exclude himself from any contracting or subcontracting with
any agency of the United States Government and from eligibility for or
involvement in nonprocurement programs of the United States Government
as defined in the debarment regulations at 45 CFR Part 76; and
(2) to exclude himself from serving in any advisory capacity to
PHS, including but not limited to service on any PHS advisory
committee, board, and/or peer review committee, or as a consultant.
FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453-8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E6-19888 Filed 11-22-06; 8:45 am]
BILLING CODE 4150-31-P
